By a News Reporter-Staff News Editor at Clinical Oncology Week -- New research on Oncology is the subject of a report. According to news originating from Chengdu, People's Republic of China, by NewsRx correspondents, research stated, "Conventional liver targeted system focuses on delivering drugs to liver, bringing toxicity on hepatic normal tissues. The purpose of this study is to construct a new system capable of specially targeting to hepatic carcinoma instead of the whole liver."
Our news journalists obtained a quote from the research from Chengdu University, "Based on the fact that nanoparticles (NPs) bound with either biotin or avidin tend to accumulate in tumors and avidin-attached reagents were quickly eliminated from blood circulation and assembled in liver, trans-resveratrol loaded chitosan nanoparticles (CS-NPs), CS-NPs with the surface modified either by biotin (B-CS-NPs) or by both biotin and avidin (A-B-CS-NPs) were prepared and their physiochemical properties were investigated. The in vitro release profiles of the three NPs all conformed to bioexponential equation. Pharmacokinetic experiment indicated that A-B-CS-NPs rapidly assembled in liver after injection, with the highest liver targeting index of 2.70, while the modification of biotin attenuated the liver targeting ability of NPs. Inhibitory study on HepG2 cells declared that compared to trans-resveratrol solution and CS-NPs, both B-CS-NPs and A-B-CS-NPs significantly improved the anticancer activity. When incubated with HepG2 cells at high concentration for longer time, A-B-CS-NPs exhibited superior cytotoxicity than B-CS-NPs."
According to the news editors, the research concluded: "This study exclaims that A-B-CS-NPs may be a potent drug delivery vector specially targeting to hepatic carcinoma."
For more information on this research see: Trans-resveratrol loaded chitosan nanoparticles modified with biotin and avidin to target hepatic carcinoma. International Journal of Pharmaceutics, 2013;452(1-2):355-62. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
The news correspondents report that additional information may be obtained from L. Bu, Key Laboratory of Sichuan Province of Medicinal Chemistry, Chengdu University, Chengdu 610106, People's Taiwan. Additional authors for this research include L.C. Gan, X.Q. Guo, F.Z. Chen, Q. Song, Qi-Zhao., X.J. Gou, S.X. Hou and Q. Yao (see also Oncology).
Keywords for this news article include: Asia, Avidin, Biotin, Chengdu, Oncology, Carcinoma, Coenzymes, Ovalbumin, Nanoparticle, Glycoproteins, Micronutrient, Hepatic Cancer, Nanotechnology, Dietary Proteins, Diet and Nutrition, Emerging Technologies, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC